Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1989-8-25
|
pubmed:abstractText |
The effects of 3-acetylpyridine (3-AP) administration to rats on the mesotelencephalic dopamine system were assessed. A single 3-AP injection resulted in biochemical and immunohistochemical evidence of degeneration of the nigrostriatal dopamine system. Six weeks after 3-AP treatment decreases in both striatal dopamine content and the activity of the catecholamine biosynthetic enzyme tyrosine hydroxylase were observed. Immunohistochemical examination suggested a decreased density of striatal tyrosine hydroxylase-immunoreactive fibers and revealed the emergence of a distinctly patchy organization of the dopamine innervation to the dorsolateral striatum. While 3-AP administration resulted in biochemical and anatomical data consistent with the degeneration of nigrostriatal dopamine fibers, no significant changes in dopamine content or the density or pattern of tyrosine hydroxylase-immunoreactive fibers in the anteromedial prefrontal cortex or nucleus accumbens were seen. These data suggest that 3-AP administration may result in a relatively specific degeneration of the nigrostriatal dopamine system. Since 3-AP causes both a profound loss of the climbing fiber input to the cerebellum derived from the inferior olivary nucleus, and the degeneration of nigrostriatal dopamine neurons, 3-AP administration may provide a useful model of olivopontocerebellar atrophy-associated parkinsonism. Moreover, the differences in the neurotoxicity caused by 3-AP and that elicited by another pyridine which causes striatal dopamine depletion (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPTP) may offer important insights into the mechanisms of both species- and site-specific pyridine neurotoxins.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0014-4886
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
105
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1-9
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:2568269-Animals,
pubmed-meshheading:2568269-Corpus Striatum,
pubmed-meshheading:2568269-Dopamine,
pubmed-meshheading:2568269-Immunohistochemistry,
pubmed-meshheading:2568269-Male,
pubmed-meshheading:2568269-Nerve Degeneration,
pubmed-meshheading:2568269-Olivopontocerebellar Atrophies,
pubmed-meshheading:2568269-Parkinson Disease,
pubmed-meshheading:2568269-Pyridines,
pubmed-meshheading:2568269-Rats,
pubmed-meshheading:2568269-Rats, Inbred Strains,
pubmed-meshheading:2568269-Spinocerebellar Degenerations,
pubmed-meshheading:2568269-Substantia Nigra,
pubmed-meshheading:2568269-Tyrosine 3-Monooxygenase
|
pubmed:year |
1989
|
pubmed:articleTitle |
3-Acetylpyridine-induced degeneration of the nigrostriatal dopamine system: an animal model of olivopontocerebellar atrophy-associated parkinsonism.
|
pubmed:affiliation |
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06508.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|